Clinical Trials Directory

Trials / Completed

CompletedNCT07230548

Effect of Four Different Diagnostic Eye Drops on Tear Film Thickness

Effect of Single Instillation of Four Different Diagnostic Eye Drops on Tear Film Thickness in Healthy Subjects

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Medical University of Vienna · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The use of topical anesthesia as well as corneal vital staining with fluorescein is an inevitable part of various ophthalmological examinations and surgical treatments. However, eye drops that don't come in single dose packages are required to contain preservatives such as chlorhexidine diacetate. An increasing number of surveys proves the partly severe side effects that preservative-containing eye drops may induce. The aim of the present study therefore is to investigate the effects of four different topical diagnostic eye drops (Novain®, Minims Oxybuprocaine Hydrochloride®, Thilorbin® and Minims®) on tear film thickness in healthy subjects. Tear film thickness will be measured at baseline and at defined time points after single instillation. The course of tear film thickness during the study day will provide information about the influence on tear film stability of the four different eye drops. Healthy subjects will receive Novain®, Minims Oxybuprocaine Hydrochloride®, Thilorbin® and Minims® eye drops on 4 different study days in a randomized order. Assessment of lipid layer thickness will be performed before and at pre-specified time points after instillation as secondary outcome. Other clinical measures such as determination of tear film break up time (TFBUT), corneal sensation, and Schirmer I test will be performed. The study will be conducted in a randomized, single masked, observer blinded four-way cross-over design. Subjects will receive all four diagnostic eye drops on 4 different study days in a randomized order.

Conditions

Interventions

TypeNameDescription
DRUGOxybuprocaine MDUthe effect of instillation of 30µl of oxybuprocaine preserved as multi-dose unit (MDU) in both eyes will be investigated
DRUGOxybuprocaine SDUthe effect of instillation of 30µl of oxybuprocaine preserved as single-dose unit (SDU) in both eyes will be investigated
DRUGOxybuprocaine/fluorescein SDUthe effect of instillation of 30µl of oxybuprocaine/fluorescein preserved as single-dose unit (SDU) in both eyes will be investigated
DRUGFluorescein SDUthe effect of instillation of 30µl of fluorescein preserved as single-dose unit (SDU) in both eyes will be investigated

Timeline

Start date
2020-06-10
Primary completion
2020-10-28
Completion
2020-10-28
First posted
2025-11-17
Last updated
2025-11-17

Locations

1 site across 1 country: Austria

Source: ClinicalTrials.gov record NCT07230548. Inclusion in this directory is not an endorsement.